NCT01603446View on ClinicalTrials.gov

L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

December 31, 2013

Conditions
MELAS Syndrome
Interventions
DRUG

L-Arginine

NOW® L-Arginine powder

Trial Locations (1)

M5V1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT01603446 - L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome | Biotech Hunter | Biotech Hunter